RECURSION PHARMACEUTICALS ($NASDAQ:RXRX) revealed their second quarter FY2023 earnings results on June 30 2023. Compared to the same period in the previous financial year, total revenue for the quarter increased by 44.1% to USD 11.0 million, while net income decreased from -65.6 million to -76.7 million.
On Tuesday, RECURSION PHARMACEUTICALS reported positive earnings results for the 2nd quarter of FY2023. Investors gave a positive response to the news as stock opened at $10.7 and closed at $11.6, up by 4.7% from the previous closing price of $11.0. The strong quarterly results were attained through RECURSION PHARMACEUTICALS’ strong commitment to developing innovative treatments for rare diseases and cancer, as well as the company’s ability to penetrate new markets. Moreover, the company’s strong partnerships with leading hospitals and research institutes have enabled them to increase their reach and availability in different countries. The positive earnings results are a result of RECURSION PHARMACEUTICALS’ efficiency in delivering products to customers, managing costs, and leveraging partnerships.
Furthermore, the company’s investments in R&D and its efficient marketing strategy have resulted in increased sales and profits for the company. The strong results in the 2nd quarter of FY2023 reflect RECURSION PHARMACEUTICALS’ efforts to generate higher revenues and profits. The company is expected to continue to build on its success as they aim to further strengthen their position in the pharmaceutical industry. With its robust product pipeline, RECURSION PHARMACEUTICALS is expected to continue to deliver strong financial performance in the coming quarters. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Recursion Pharmaceuticals. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Recursion Pharmaceuticals. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Recursion Pharmaceuticals. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Recursion Pharmaceuticals are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Recursion Pharmaceuticals Intrinsic Value Calculation
At GoodWhale, we’ve conducted an in-depth analysis of RECURSION PHARMACEUTICALS’ fundamentals, and concluded that the fair value of the company’s share is around $42.7. We arrived at this figure using our proprietary Valuation Line model, which takes into account a variety of factors such as the company’s history, revenue, and industry position. At the moment, RECURSION PHARMACEUTICALS’ stock is traded at $11.6, which means it’s currently undervalued by 72.8%, representing an excellent opportunity for investors. For those looking to invest in a company that offers a solid long-term potential, RECURSION PHARMACEUTICALS is certainly a strong contender. More…
Risk Rating Analysis
Star Chart Analysis
The company was founded in 2013 by Christopher R. Gibson and Brendan Frey. Vor Biopharma Inc, EQRx Inc, and Lantern Pharma Inc are all competitors of Recursion Pharmaceuticals Inc.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with serious and life-threatening diseases. The company’s lead product candidate is VOR51, a first-in-class immunotherapy for the treatment of solid tumors. Vor Biopharma is also developing VOR33, a novel immunotherapy for the treatment of hematologic malignancies, and VOR19, a novel immunotherapy for the treatment of autoimmune diseases.
EQRx is a biopharmaceutical company that focuses on the development of innovative therapies for patients with serious diseases. The company has a market cap of $2.42 billion and a return on equity of -12.39%. EQRx is headquartered in Cambridge, Massachusetts.
Lantern Pharma Inc has a market cap of 46.57M as of 2022. The company’s return on equity is 16.74%.
Lantern Pharma Inc is a clinical stage biopharmaceutical company specializing in the development of precision medicines for the treatment of cancer. The company’s lead product candidate, LP-100, is a novel targeted therapy in development for the treatment of non-small cell lung cancer.
Recursion Pharmaceuticals reported strong financial results for their second quarter of FY2023, with total revenue increasing 44.1% year-over-year to 11.0 million USD. Net income decreased significantly to -76.7 million USD, however the company’s stock price moved up on the same day, indicating that investors have confidence in the long-term prospects of the company. With an impressive revenue growth and long-term potential, Recursion Pharmaceuticals could be an interesting investment option for investors looking for growth opportunities in the healthcare sector.